Skip to NavigationSkip to content

brexit

Pharmafile.com's top ten stories of 2017

After a packed year that has flown by, we've reached the final top ten of 2017. Below you can find the biggest stories of the year that proved most popular with our readers.

It's been a year characterised by uncertainty and scandal, but eventful throughout. From J&J's massive acquisition of Actelion bringing in the year, to Teva's increasingly tragic fall from grace and the shadows cast on the industry and beyond by President Trump and Brexit, 2017 was a standout year for more than just a few reasons.

EMA Headquarters: There’s no place like home

Published on 13/11/17 at 11:07am

With the result of the Brexit referendum, the future of the EMA’s London headquarters was cast in doubt. Now, 19 EU member states are bidding to become the new home of the agency. It's now only one week away from the decision as to which city will host the agency and the competition is fierce.

The November 2017 issue of Pharmafocus is now live!

The November edition of Pharmafocus is now live and available to read online here!

AstraZeneca Chairman wants three-year Brexit transition period

The Chairman of AstraZeneca, Leif Johansson, revealed in no uncertain terms that his company would like there to be a three-year Brexit transition period.

In comments made to Swedish daily newspaper, Dagens Nyheter, he made the company’s desire for clarity from the government perfectly clear by stating that business needed “at least three years” for the transition period and “and very early in that period, we need to know what to expect in years four, five and six”.

EMA relocation will cause drug approval delays even in best case scenario, agency says

As a direct result of the UK’s referendum vote to leave the EU last year, the headquarters of the EMA, currently located in Canary Wharf, London, will be forced to relocate to another EU member state.

19 countries are bidding to become the new host, with the final verdict to be reached next month. Concerns have been rife over the disruption which this upheaval will cause to the agency’s workflow, and now the EMA itself has warned that, at best, we can expect approval delays and, at worst, limited drug availability as its resources are put under duress.

UK’s post-Brexit strategy looks to life sciences industry

The UK Government had already announced, as part of its industrial plan, that the life sciences were regarded as a key part of British industry when looking towards a post-Brexit industrial future. Developing this further, a report has been delivered that aims to set out exactly how the industry can become a pillar of the UK economy.

EMA reveals 'business continuity plan' for Brexit, cuts resources from non-essential areas

The uncertainty caused by Brexit has been and continues to be far-reaching, and perhaps most impactful for business, organisations and their practices. The EMA is no exception, and due to the anticipated disruption surrounding the outcome of negotiations, the agency has released a continuity plan outlining its intentions to mitigate implications on its workload.

Brexit Health Alliance warns that UK/EU negotiations put patients at risk

Last month saw the formation of the Brexit Health Alliance, a partnering of key pharma and life sciences organisations including the ABPI, the BioIndustry Association and NHS Providers, all dedicated to vocalising and protect their collective interests throughout the negotiation process for the UK’s exit from the EU.

Top Ten most popular articles on Pharmafile.com this week

The week was characterised by two big psoriasis approval stories, while Amgen's osteoporosis treatment was knocked back. Novartis CEO Joe Jimenez's comments regarding the 2018 outlook for the company were of strong consequence to many readers in the industry, while Merck's restructure announcement was less positive, promising the layoff of 200 employees.

What pharma should know about the European Unitary Patent in light of Brexit

Published on 17/07/17 at 10:46am

The departure of the United Kingdom from the European Union, dubbed “Brexit,” has sparked significant economic global uncertainty. Two Brexit-related issues especially relevant to the pharmaceutical industry are: 1) whether the UK will ratify the proposed European Unitary Patent System, and 2) whether London will still be the site of the thematic patent court dedicated to pharmaceutical patent disputes.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches